ArticleAmerican journal of physiology. Renal physiology2013
Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).
Article in American journal of physiology. Renal physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04646408 (Determinants of Cardiovascular Disease, Kidney Disease and Diabetes in People of African Ancestry With HIV), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determinants of Cardiovascular Disease, Kidney Disease and Diabetes in People of African Ancestry With HIV (CKD Study)
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.BMC nephrology · 2025Review
- Health Disparities at the Intersection of Racism, Social Determinants of Health, and Downstream Biological Pathways.International journal of environmental research and public health · 2025Review
- Article
- Iron therapy mitigates chronic kidney disease progression by regulating intracellular iron status of kidney macrophages.JCI insight · 2023Article
- GSTM1 Copy Number and Kidney Disease in People With HIV.Kidney international reports · 2022Article
- Association of GSTM1 Deletion With Progression of CKD in Children: Findings From the Chronic Kidney Disease in Children (CKiD) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Observational
- Pharmacogenomic analysis of a genetically distinct Indigenous population.The pharmacogenomics journal · 2022Article
- Article
- Article
- Review
- Discovering the Protective Effects of Resveratrol on Aflatoxin B1-Induced Toxicity: A Whole Transcriptomic Study in a Bovine Hepatocyte Cell Line.Antioxidants (Basel, Switzerland) · 2021Article
- Comprehensive analysis of the long non-coding RNA expression profile and functional roles in a contrast-induced acute kidney injury rat model.Experimental and therapeutic medicine · 2021Article
- Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease.Nutrients · 2021Review
- Case Report: Novel Dietary Supplementation Associated With Kidney Recovery and Reduction in Proteinuria in a Dialysis Dependent Patient Secondary to Steroid Resistant Minimal Change Disease.Frontiers in pediatrics · 2021Article
- GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu.Oxidative medicine and cellular longevity · 2021Article
- Identifying Biomarkers from Transcriptomic Signatures in Renal Allograft Biopsies Using Deceased and Living Donors.Frontiers in immunology · 2021Article
- Beneficial Effects ofNutrients · 2020Article
- Article
- Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease.JCI insight · 2019Article
- Direct and indirect inhibition of the circadian clock protein Per1: effects on ENaC and blood pressure.American journal of physiology. Renal physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Oxidative stress is acknowledged to play a role in kidney disease progression. Genetic variants that affect the capacity to handle oxidative stress may therefore influence the outcome of kidney disease. We examined whether genetic variants of the GSTM1 gene, a member of a superfamily of glutathione S-transferases, influence the course of kidney disease progression in participants of the African American Study of Kidney Disease (AASK) trial. Groups with and without the common GSTM1 null allele, GSTM1(0), differed significantly in the time to a glomerular filtration rate (GFR) event or dialysis (P = 0.04) and in the time to GFR event, dialysis, or death (P = 0.02). The hazard ratios (HR) for the time to a GFR event or dialysis in those with two or one null allele relative to those possessing none were 1.88 [95% confidence interval (CI), 1.07 to 3.30, P = 0.03] and 1.68 (95% CI, 1.00 to 2.84, P < 0.05), respectively. For the time to GFR event, dialysis, or death, the HR for two null alleles was 2.06 (95% CI, 1.20 to 3.55, P = 0.01) and for one null allele 1.70 (95% CI, 1.02 to 2.81, P = 0.04). We demonstrated that GSTM1 directly regulates intracellular levels of 4-hydroxynonenal (4-HNE) in vascular smooth muscle cells. Furthermore, we showed that renal 4-HNE levels and GSTM1 are both increased after reduction of renal mass (RRM) in the mouse. We conclude that GSTM1 is normally upregulated in chronic kidney disease (CKD) in a protective response to increased oxidative stress. A genetic variant that results in loss of GSTM1 activity may be deleterious in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.